Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/E ratio is N/A as of 2026-10-06T18:31:49.347Z.
Calculation as of: 2026-10-06T18:31:49.347Z.
Quote observation: 2026-10-06T18:29:47.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 8a37bf5da35164cf1f35689d787409f81d347c26e3158920307b7793dc95150d
PE RATIO
N/A
Market Cap
$59.09M
PE Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | PE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| MiNK Therapeutics, Inc. (INKT) | $58.69M | N/A | N/A | N/A | N/A |
| Connect Biopharma Holdings Limited (CNTB)vs › | $59.09M | N/A | N/A | N/A | N/A |
| Boundless Bio, Inc. (BOLD)vs › | $57.98M | N/A | N/A | N/A | N/A |
| PDS Biotechnology Corporation (PDSB)vs › | $57.88M | N/A | N/A | N/A | N/A |
| Adicet Bio, Inc. (ACET)vs › | $59.81M | N/A | 110.41 | 110.41 | 110.41 |
| Talphera, Inc. (TLPH)vs › | $57.09M | N/A | 0.43 | 0.43 | 0.43 |
| Oncolytics Biotech Inc. (ONCY)vs › | $59.93M | N/A | N/A | N/A | N/A |
| Kalaris Therapeutics Inc (KLRS)vs › | $60.68M | N/A | N/A | N/A | N/A |
| Xilio Therapeutics, Inc. (XLO)vs › | $60.03M | N/A | N/A | N/A | N/A |
| OKYO Pharma Limited (OKYO)vs › | $56.98M | N/A | N/A | N/A | N/A |
Trailing P/E
N/A
Forward P/E
N/A
Forward P/E is calculated using analyst consensus EPS estimates for the current or next fiscal year.
Calculation:
Current Price
$11.78
Forward EPS (Est.)
$-2.48
Forward P/E
N/A
Source: FMP Analyst Consensus Estimates. Forward EPS represents the average analyst estimate for the nearest fiscal year.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
